SCHEMBL17350085

SCHEMBL17350085

Cc1cccc(Oc2ccc(NC(=O)[C@@H](C)N)cn2)c1C.Cc1cccc(Oc2ccc(NC(=O)[C@@H](C)NC(=O)OC(C)(C)C)cn2)c1C

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.43
JAK2 O60674 2/20 0.41
LMNA P02545 1/20 0.40
HTR2C P28335 2/20 0.38
XIAP P98170 1/20 0.37
KDM4E B2RXH2 1/20 0.37
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
ALDH1A1 P00352 1/20 0.36
POLB P06746 1/20 0.36
RAB9A P51151 1/20 0.35
TSHR P16473 1/20 0.35
HSD17B10 Q99714 1/20 0.35
SUV39H2 Q9H5I1 1/20 0.35
EGFR P00533 1/20 0.35
EPHX2 P34913 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
NOTUM Q6P988 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12593952 0.95 KEAP1 (0.45) KEAP1JAK2LMNAHTR2CKDM4E
SCHEMBL1979857 0.87 KEAP1 (0.55) KEAP1LMNAHTR2CXIAPKMT2A
SCHEMBL12594159 0.87 KMT2A (0.45) JAK2HTR2CKDM4EKMT2AMEN1
SCHEMBL17350075 0.86 JAK2 (0.42) JAK2LMNAHTR2CXIAPKMT2A
SCHEMBL12594157 0.86 JAK2 (0.42) JAK2HTR2CKDM4EKMT2AMEN1
SCHEMBL21980930 0.81 KEAP1 (0.38) KEAP1JAK2LMNAHTR2CKMT2A
SCHEMBL13268380 0.81 HTT (0.45) KEAP1LMNAHTR2CKMT2AMEN1
SCHEMBL12594056 0.81 JAK2 (0.43) JAK2LMNAHTR2CKMT2AMEN1
SCHEMBL12594058 0.80 JAK2 (0.41) JAK2KDM4EKMT2AMEN1ALDH1A1
SCHEMBL13720643 0.80 KEAP1 (0.43) KEAP1LMNAHTR2CXIAPKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 US disclosed
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-11-29 US disclosed
US-10058551-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2018-08-28 US disclosed
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-01-25 US disclosed
US-9849131-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2017-12-26 US disclosed
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2017-03-09 US disclosed
EP-2509961-B1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LTD (GB) 2016-03-09 EP disclosed
US-9216967-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2015-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 KEAP1 3193/4885JAK2 1654/4885LMNA 2187/4885
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 KEAP1 3193/4885JAK2 1654/4885LMNA 2187/4885
US-10632118-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 KEAP1 3193/4885JAK2 1654/4885LMNA 2187/4885
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 KEAP1 3193/4885JAK2 1654/4885LMNA 2187/4885
US-10058551-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 KEAP1 3193/4885JAK2 1654/4885LMNA 2187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.